Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Melanoma 34Carcinoma, Non-Small-Cell Lung 22Carcinoma, Renal Cell 20Neoplasm Metastasis 13Carcinoma, Hepatocellular 10Brain Neoplasms 8Lung Neoplasms 7Skin Neoplasms 6Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Kidney Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Ovarian Neoplasms 4Myelodysplastic Syndromes 4Multiple Myeloma 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Sarcoma 3Recurrence 3Mesothelioma 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Histiocytoma, Malignant Fibrous 3

Interventions

Cisplatin 18Gemcitabine 14Radiotherapy, Intensity-Modulated 11Magnetic Resonance Spectroscopy 8toripalimab 7Specimen Handling 7Capecitabine 7Platinum 5Drug Therapy 51,2-diaminocyclohexaneplatinum II citrate 5camrelizumab 4Radiotherapy 4Nivolumab 4spartalizumab 3sintilimab 3anlotinib 3Immunoglobulin G 3Immune Checkpoint Inhibitors 3Docetaxel 3Disulfides 3atezolizumab 2Radiation 2Phantoms, Imaging 2Ipilimumab 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 218-O-demethylcervinomycin A2 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Ipilimumab × 90 days × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT05904080 2026-05-18

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡